• Sethapong Lertsakulbunlue Department of Pharmacology, Phramongkutklao College of Medicine
  • Passawith Kunsuwan Fort Wachirawut Hospital, Nakhon Si Thammarat
  • Ram Rangsin Department of Military and Community Medicine, Phramongkutklao College of Medicine
  • Boonsub Sakboonyarat Department of Military and Community Medicine, Phramongkutklao College of Medicine
Keywords: Tuberculosis, Mortality, Diabetes, Community hospital, Thailand


Background: Tuberculosis (TB), a communicable disease, is currently a significant health problem in Thailand. Type 2 diabetes (T2D) is an indicator of poor TB outcomes; however, data according to specific antihyperglycemic use and tuberculosis outcomes in community hospital settings in Thailand remain limited. We aimed to determine TB mortality as well as explore the demographic and clinical risk factors among patients with pulmonary TB and underlying T2D.

Methods: A retrospective cohort study was conducted between January 1, 2013, and December 31, 2020, to determine tuberculosis mortality and its risk factors among patients with T2D and pulmonary TB visiting three community hospitals, in central Thailand. T2D and pulmonary TB were determined according to the International Classification of Diseases, Tenth Revision codes presented in medical records. TB mortality data were reviewed and retrieved from the tuberculosis treatment cards. Patients were classified as “dead” when they died before completing treatment regardless of the causes. Multivariable cox proportional regression analysis was performed to obtain the adjusted hazard ratios (AHR) and 95% confidence interval (CI) of factors related to TB mortality.

Results: A total of 133 patients with T2D and pulmonary TB were enrolled in the present study; 74 (55.6%) participants were males. At baseline, the average age of participants was 57.29+12.51 years. During the study period, the TB mortality rate was 15.74 (95% CI 8.13-27.50) deaths per 100 person-years. The independent risk factors for TB mortality included age ≥70 years (AHR 5.45, 95% CI; 1.36-21.84), use of insulin (AHR 4.62, 95% CI; 1.11-19.21), and positive sputum test result at 1st follow-up (AHR 16.10, 95% CI; 2.10-123.40).

Conclusion: TB mortality among patients with T2D should be emphasized. Insulin use may be a proxy indicator for poor glycemic control associated with mortality. Additionally, elderly patients should be closely observed for successful treatment as well as monitoring for any adverse events.


Download data is not yet available.


World Health Organization. Global tuberculosis report 2020 [Internet]. 2021 [cited 2022 Mar 15]. Available from: https://www.who.int/publications/i/item/9789240013131

Diabetes Association of Thailand under The Patronage of Her Royal Highness Princess Maha Chakri Sirindhorn, Endocrine Society of Thailand, Department of Medical Services, Ministry of Public Health, Office NHS. Clinical Practice Guideline for Diabetes 2017. Bangkok, Thailand; 2017.

Wichai Aekplakorn. Thai National Health Examination VI (NHES VI) [Internet]. 2019 [cited 2022 Jan 12]. Available from: https://online.fliphtml5.com/bcbgj/znee/#p=187

Sakboonyarat B, Rangsin R. Prevalence and associated factors of ischemic heart disease (IHD) among patients with diabetes mellitus: a nation-wide, cross-sectional survey. BMC Cardiovasc Disord 2018; 18: 151. DOI: https://doi.org/10.1186/s12872-018-0887-0

Euswas N, Phonnopparat N, Morasert K, Thakhampaeng P, Kaewsanit A, Mungthin M, et al. National trends in the prevalence of diabetic retinopathy among Thai patients with type 2 diabetes and its associated factors from 2014 to 2018. PLoS One 2021; 16: e0245801. DOI: https://doi.org/10.1371/journal.pone.0245801

Wittayatechakul P, Hanyos P, Rangsin R, Sakboonyarat B. Incidence and risk factors of diabetic retinopathy among patients with type 2 diabetes in a community hospital, central Thailand. J Southeast Asian Med Res 2021; 5: 11–20. DOI: https://doi.org/10.55374/jseamed.v5i1.87

Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One 2017; 12: 4 DOI: https://doi.org/10.1371/journal.pone.0175925

Zheng C, Hu M, Gao F. Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden. Glob Health Action 2017; 10: 1-11. DOI: https://doi.org/10.1080/16549716.2016.1264702

Gautam S, Shrestha N, Mahato S, Nguyen TPA, Mishra SR, Berg-Beckhoff G. Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: a systematic review and meta-analysis. Sci Rep 2021; 11: 1-2. DOI: https://doi.org/10.1038/s41598-021-81057-2

Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med 2011; 9: 1-5. DOI: https://doi.org/10.1186/1741-7015-9-81

Heo EY, Choi NK, Yang BR, Koo BK, Hwang SS, Lee CH, et al. Tuberculosis is frequently diagnosed within 12 months of diabetes mellitus. Int J Tuberc Lung Dis 2015; 1: 1098-101. DOI: https://doi.org/10.5588/ijtld.14.0772

Kamper-Jørgensen Z, Carstensen B, Norredam M, Bygbjerg IC, Andersen PH, Jørgensen ME. Diabetes-related tuberculosis in Denmark: Effect of ethnicity, diabetes duration and year of diagnosis. Int J Tuberc Lung Dis 2015; 19: 1169-75. DOI: https://doi.org/10.5588/ijtld.14.0932

Kumpatla S, Sekar A, Achanta S, Sharath BN, Kumar AM v., Harries AD, et al. Characteristics of patients with diabetes screened for tuberculosis in a tertiary care hospital in South India. Public Health Action 2013; 3: 23-8. DOI: https://doi.org/10.5588/pha.13.0035

Aungkulanon S, Tangcharoensathien V, Shibuya K, Bundhamcharoen K, Chongsuvivatwong V. Area-level socioeconomic deprivation and mortality differentials in Thailand: Results from principal component analysis and cluster analysis. Int J Equity Health 2017; 16: 1-12. DOI: https://doi.org/10.1186/s12939-017-0613-z

Pengpid S, Peltzer K, Puckpinyo A, Tiraphat S, Viripiromgool S, Apidechkul T, et al. Knowledge, attitudes, and practices about tuberculosis and choice of communication channels in Thailand. J Infect Dev Ctries 2016; 10: 694-703. DOI: https://doi.org/10.3855/jidc.6963

Cai J, Wang X, Ma A, Wang Q, Han X, Li Y. Factors associated with patient and provider delays for tuberculosis diagnosis and treatment in Asia: A systematic review and meta-analysis. PLoS One 2015; 10: e0120088. DOI: https://doi.org/10.1371/journal.pone.0120088

Sakboonyarat B, Rangsin R, Kantiwong A, Mungthin M. Prevalence and associated factors of uncontrolled hypertension among hypertensive patients: A nation-wide survey in Thailand. BMC Res Notes 2019; 12: 1-8. DOI: https://doi.org/10.1186/s13104-019-4417-7

Charoensakulchai S, Lertpheantum C, Aksornpusitpong C, Trakulsuk P, Sakboonyarat B, Rangsin R, et al. Six-year trend and risk factors of unsuccessful pulmonary tuberculosis treatment outcomes in Thai Community Hospital. BMC Res Notes 2021; 14: 89. DOI: https://doi.org/10.1186/s13104-021-05504-z

Bureau of Tuberculosis D of DCM of PHT. National Tuberculosis Control Programme Guidelines, Thailand 2018. 1st ed. Aksorn Graphic and Design Publishing Limited Partnership; 2018, 76.

Nguyen DT, Graviss EA. Diabetic trends and associated mortality in tuberculosis patients in Texas, a large population-based analysis.Tuberculosis 2019; 116: 59-65. DOI: https://doi.org/10.1016/j.tube.2019.04.011

Nguyen CH, Pascopella L, Barry PM. Association between diabetes mellitus and mortality among patients with tuberculosis in California, 2010-2014. Int J Tuberc Lung Dis 2018; 22: 1269-76. DOI: https://doi.org/10.5588/ijtld.18.0011

Hase I, Toren KG, Hirano H, Sakurai K, Horne DJ, Saito T, et al. Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation. Drugs Aging 2021; 38: 807-15. DOI: https://doi.org/10.1007/s40266-021-00880-4

Charoensakulchai S, Limsakul M,Saengungsumalee I, Usawachoke S, Udomdech A, Pongsaboripat A, et al. Characteristics of Poor Tuberculosis Treatment Outcomes among Patients with Pulmonary Tuberculosis in Community Hospitals of Thailand. Am J Trop Med Hyg 2020; 102: 553–61. DOI: https://doi.org/10.4269/ajtmh.19-0564

Dooley KE, Lahlou O, Ghali I, Knudsen J, Elmessaoudi MD, Cherkaoui I, et al. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health 2011; 11: 1-7. DOI: https://doi.org/10.1186/1471-2458-11-140

Anunnatsiri S, Chetchotisakd P, Wanke C. Factors associated with treatment outcomes in pulmonary tuberculosis in northeastern Thailand. Southeast Asian J Trop Med Public Health 2005; 36: 324-30.

Ma Y, Pang Y, Shu W, Liu YH, Ge QP, Du J, et al. Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from a 3-year follow-up. Eur J Clin Microbiol Infect Dis 2018; 37: 1259-63. DOI: https://doi.org/10.1007/s10096-018-3242-6

Marupuru S, Senapati P, Pathadka S, Miraj SS, Unnikrishnan MK, Manu MK. Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility. Braz J Infect Dis 2017; 21: 312-16. DOI: https://doi.org/10.1016/j.bjid.2017.01.001

Degner NR, Wang JY, Golub JE, Karakousis PC. Metformin Use Reverses the Increased Mortality Associated with Diabetes Mellitus during Tuberculosis Treatment. Clin Infect Dis 2018; 66: 198-205. DOI: https://doi.org/10.1093/cid/cix819

Teles RMB, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013; 339: 1448-53. DOI: https://doi.org/10.1126/science.1233665

Lienard J, Movert E, Valfridsson C, Sturegård E, Carlsson F. ESX-1 exploits type I IFN-signalling to promote a regulatory macrophage phenotype refractory to IFNγ- mediated autophagy and growth restriction of intracellular mycobacteria. Cell Microbiol 2016; 18: 1471-85. DOI: https://doi.org/10.1111/cmi.12594

Berry MPR, Graham CM, McNab FW, Xu Z, Bloch SAA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-7. DOI: https://doi.org/10.1038/nature09247

Oglesby W, Kara AM, Granados H, Cervantes JL. Metformin in tuberculosis: beyond control of hyperglycemia. Infection 2019; 47: 697-702. DOI: https://doi.org/10.1007/s15010-019-01322-5

Sakboonyarat B, Pima W, Chokbumrungsuk C, Pimpak T, Khunsri S, Ukritchon S, et al. National trends in the prevalence of glycemic control among patients with type 2 diabetes receiving continuous care in Thailand from 2011 to 2018. Sci Rep 2021; 11: 14260. DOI: https://doi.org/10.1038/s41598-021-93733-4

Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Prato S del, et al. Insulin therapy in people with type 2 diabetes: Opportunities and challenges. Diabetes Care 2014; 37: 1495-1508. DOI: https://doi.org/10.2337/dc13-2743

Donnelly JP, Nair S, Griffin R, Baddley JW, Safford MM, Wang HE, et al. Association of diabetes and insulin therapy with risk of hospitalization for infection and 28-day mortality risk. Clin Infect Dis 2017; 64: 435-42.

How to Cite
Lertsakulbunlue S, Kunsuwan P, Rangsin R, Sakboonyarat B. PULMONARY TUBERCULOSIS MORTALITY AND ITS RISK FACTORS AMONG PATIENTS WITH TYPE 2 DIABETES AND PULMONARY TUBERCULOSIS IN FOUR COMMUNITY HOSPITALS, CENTRAL THAILAND. J Southeast Asian Med Res [Internet]. 2022Sep.3 [cited 2022Oct.7];60:e0120. Available from: https://www.jseamed.org/index.php/jseamed/article/view/120
Original Articles

Most read articles by the same author(s)